Drug intelligence / Profile preview

Folidoce

Development stage: Unknown
Lead developer: Italfarmaco
Modality: Small Molecules
Administration: Oral

Overview

Folidoce is an oral vitamin supplement combination containing 400 micrograms of folic acid and 2 micrograms of vitamin B12 (cyanocobalamin). It is primarily used as an antianemic preparation and for the prevention of neural tube defects in women planning pregnancy or during the first trimester of pregnancy. Folic acid is essential for DNA synthesis and cell division, while vitamin B12 acts as a cofactor for methionine synthase, which is critical for the regeneration of tetrahydrofolate. The product is marketed in Turkey by ITF İlaç Sanayi ve Ticaret, a subsidiary of Italfarmaco SpA.

Brand names: Folidoce

Targets

MTR (Methionine synthase)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on Folidoce.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Folidoce.

Explore the full profile